NSRX
insider transactionsNasus Pharma Ltd — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+17.9K
17.9K buy · 0 sell
Net value · 365d
$41.5K
$41.5K in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
2
17.9K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Chief Executive Officer
$10.9K
2.9K sh · $3.76
Own +2%
-
Buy·P
Chief Executive Officer
$30.6K
15.0K sh · $2.04
Own +240%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 22, 2026 | Dan Benjamin Teleman KEY | Buy P | 2.9K | $10.9K |
| Mar 31, 2026 | Dan Benjamin Teleman KEY | Buy P | 15.0K | $30.6K |
About NSRX insider trading
This page tracks insider transactions for Nasus Pharma Ltd (NSRX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.